High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
Standard
High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. / Wild, Peter J; Kunz-Schughart, Leoni A; Stoehr, Robert; Burger, Maximilian; Blaszyk, Hagen; Simon, Ronald; Gasser, Thomas; Mihatsch, Michael; Sauter, Guido; Hartmann, Arndt.
In: INT J ONCOL, Vol. 27, No. 2, 2, 2005, p. 385-391.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
AU - Wild, Peter J
AU - Kunz-Schughart, Leoni A
AU - Stoehr, Robert
AU - Burger, Maximilian
AU - Blaszyk, Hagen
AU - Simon, Ronald
AU - Gasser, Thomas
AU - Mihatsch, Michael
AU - Sauter, Guido
AU - Hartmann, Arndt
PY - 2005
Y1 - 2005
N2 - To investigate whether protein expression of cyclooxygenase 2 (COX2) is associated with tumor phenotype, immunohistochemical alterations, and clinical outcome in urinary bladder cancer (BC). Tissue microarrays (n = 776) were used to analyze COX2, P53 and the Ki-67 labeling index immunohistochemically. A monoclonal mouse antibody was used after heat-induced antigen retrieval. COX2 expression was scored semiquantitatively (0-3+). COX2 expression was detected in 60% (368/617) of urothelial BC. Positive COX2 staining was seen in 77.8% (140/182) of muscle invasive urothelial BC, compared to 35% (7/20) of muscle invasive squamous cell carcinomas (p <0.001). COX2 protein expression was associated with advanced tumor stage (p <0.0001), high-grade histology (p <0.0001), solid growth pattern in invasive BC (pT1-4, p = 0.02), high Ki-67 labeling index (p <0.0001), and positive P53 IHC (p <0.001). COX2 expression was not associated with survival, recurrence, and progression in clinically relevant subgroups (pTa, pT1, pT2-4). Expression of COX2 is common in advanced BC with poor prognostic characteristics, supporting efforts to initiate clinical trials on the efficacy of COX2 inhibitors in the adjuvant treatment of high-risk urinary BC.
AB - To investigate whether protein expression of cyclooxygenase 2 (COX2) is associated with tumor phenotype, immunohistochemical alterations, and clinical outcome in urinary bladder cancer (BC). Tissue microarrays (n = 776) were used to analyze COX2, P53 and the Ki-67 labeling index immunohistochemically. A monoclonal mouse antibody was used after heat-induced antigen retrieval. COX2 expression was scored semiquantitatively (0-3+). COX2 expression was detected in 60% (368/617) of urothelial BC. Positive COX2 staining was seen in 77.8% (140/182) of muscle invasive urothelial BC, compared to 35% (7/20) of muscle invasive squamous cell carcinomas (p <0.001). COX2 protein expression was associated with advanced tumor stage (p <0.0001), high-grade histology (p <0.0001), solid growth pattern in invasive BC (pT1-4, p = 0.02), high Ki-67 labeling index (p <0.0001), and positive P53 IHC (p <0.001). COX2 expression was not associated with survival, recurrence, and progression in clinically relevant subgroups (pTa, pT1, pT2-4). Expression of COX2 is common in advanced BC with poor prognostic characteristics, supporting efforts to initiate clinical trials on the efficacy of COX2 inhibitors in the adjuvant treatment of high-risk urinary BC.
M3 - SCORING: Zeitschriftenaufsatz
VL - 27
SP - 385
EP - 391
JO - INT J ONCOL
JF - INT J ONCOL
SN - 1019-6439
IS - 2
M1 - 2
ER -
